Literature DB >> 7966603

Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

K H Leong1, A J Ramsay, D B Boyle, I A Ramshaw.   

Abstract

Avipoxviruses have recently been studied as potential vectors for the delivery of heterologous vaccine antigen. Because these viruses abortively infect mammalian cells yet still effectively present encoded foreign genes to the host immune system, they offer a safer but effective alternative to other live virus vectors. We have examined the effect of coexpressing the cytokine interleukin-6 or gamma interferon on immune responses to a recombinant fowlpox virus expressing influenza virus hemagglutinin. The encoded cytokine was expressed for prolonged periods in infected cell culture with little cytopathic effect due to the abortive nature of the infection. In mice, vector-expressed cytokine dramatically altered immune responses induced by the coexpressed hemagglutinin antigen. Expression of interleukin-6 augmented both primary systemic and mucosal antibody responses and primed for enhanced recall responses. In contrast, expression of gamma interferon markedly inhibited antibody responses without affecting the generation of cell-mediated immunity. The safety of these constructs was demonstrated in mice with severe combined immunodeficiency, and no side effects due to cytokine expression were observed. In summary, fowlpox virus vectors encoding cytokines represent a safe and effective vaccine strategy which may be used to selectively manipulate the immune response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966603      PMCID: PMC237277          DOI: 10.1128/JVI.68.12.8125-8130.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

Review 1.  Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo.

Authors:  I Ramshaw; J Ruby; A Ramsay; G Ada; G Karupiah
Journal:  Immunol Rev       Date:  1992-06       Impact factor: 12.988

2.  Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.

Authors:  W I Cox; J Tartaglia; E Paoletti
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

3.  A strategy for prophylactic vaccination against HIV.

Authors:  J Salk; P A Bretscher; P L Salk; M Clerici; G M Shearer
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

4.  Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus.

Authors:  H M Etlinger; W Altenburger
Journal:  Vaccine       Date:  1991-07       Impact factor: 3.641

5.  Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells.

Authors:  C P Chiu; C Moulds; R L Coffman; D Rennick; F Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

6.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Immunisation with canarypox virus expressing rabies glycoprotein.

Authors:  M Cadoz; A Strady; B Meignier; J Taylor; J Tartaglia; E Paoletti; S Plotkin
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

8.  Recombinant fowlpox virus inducing protective immunity in non-avian species.

Authors:  J Taylor; R Weinberg; B Languet; P Desmettre; E Paoletti
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

9.  Fowlpox virus as a vector in non-avian species.

Authors:  J Taylor; E Paoletti
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

10.  Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus.

Authors:  K Nazerian; L F Lee; N Yanagida; R Ogawa
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more
  18 in total

1.  Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2.

Authors:  B R Gundlach; H Linhart; U Dittmer; S Sopper; S Reiprich; D Fuchs; B Fleckenstein; G Hunsmann; C Stahl-Hennig; K Uberla
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Authors:  J Benson; C Chougnet; M Robert-Guroff; D Montefiori; P Markham; G Shearer; R C Gallo; M Cranage; E Paoletti; K Limbach; D Venzon; J Tartaglia; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Delivery of the p67 sporozoite antigen of Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle.

Authors:  I Gentschev; I Glaser; W Goebel; D J McKeever; A Musoke; V T Heussler
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light.

Authors:  K Tsung; J H Yim; W Marti; R M Buller; J A Norton
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.

Authors:  T Woodberry; J Gardner; L Mateo; D Eisen; J Medveczky; I A Ramshaw; S A Thomson; R A Ffrench; S L Elliott; H Firat; F A Lemonnier; A Suhrbier
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity.

Authors:  A Bukreyev; S S Whitehead; N Bukreyeva; B R Murphy; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  The genome of fowlpox virus.

Authors:  C L Afonso; E R Tulman; Z Lu; L Zsak; G F Kutish; D L Rock
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus.

Authors:  C J Dale; R De Rose; I Stratov; S Chea; D C Montefiori; S Thomson; I A Ramshaw; B E H Coupar; D B Boyle; M Law; S J Kent
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.

Authors:  Hasan Zeytin; Eva Reali; David A Zaharoff; Connie J Rogers; Jeffrey Schlom; John W Greiner
Journal:  J Interferon Cytokine Res       Date:  2008-02       Impact factor: 2.607

10.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.